Search Results for: Global Cancer Vaccine Market to
Articles
Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents April 1, 2021
Pfizer Inc. and BioNTech SE recently announced that, in a Phase 3 trial in adolescents 12 to 15 years of age with or without prior evidence of SARS-CoV-2 infection, the Pfizer-BioNTech COVID-19 vaccine BNT162b2….
EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution & Storage of Doses Across European Union March 26, 2021
Pfizer Inc. and BioNTech SE recently announced the European Medicines Agency (EMA) approved storage of COMIRNATY at -25°C to -15°C for a total of 2 weeks….
GSK & CureVac to Develop Next-Generation mRNA COVID-19 Vaccines February 4, 2021
GlaxoSmithKline plc and CureVac N.V. recently announced a new €150-million collaboration, building on their existing relationship, to jointly develop next-generation...SPECIAL FEATURE - Injection Devices: Will COVID-19 Deliver Growth to the Market? September 1, 2020
Contributor Cindy H. Dubin interviews several leading companies and highlights trends in autoinjectors, pen injectors, wearable devices and connectivity, and prefilled syringes.
GeoVax & BravoVax to Collaborate on Development of Coronavirus Vaccine January 27, 2020
GeoVax Labs, Inc. and BravoVax recently announced the signing of a Letter of Intent to jointly develop a vaccine against...Bavarian Nordic Initiates Phase 3 Trial of Vaccine June 20, 2019
Bavarian Nordic A/S recently announced the initiation of a pivotal Phase 3 trial of the freeze-dried formulation of MVA-BN smallpox...CHECKPOINT INHIBITORS - Novel Targets & Global Markets April 29, 2019
Laurie L. Sullivan and Cheryl L. Barton, PhD, say as manufacturers expand the clinical utility and healthcare professionals become more familiar with their efficacy and safety profiles, the checkpoint inhibitor market will continue to expand, becoming the cornerstone of many cancer treatment regimens.
Commercial Prospects for Immuno-Oncology Development Across Oncology Indications in Untapped Cancer Types or in Combinations November 15, 2018
Immuno-Oncology (IO) development is booming across the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) with IO agents...Innovest Global Signs Worldwide Agreement With Cedars-Sinai Medical Center to Commercialize Vaccine August 13, 2018
StemVax Therapeutics, an Innovest Global Inc. holding, has been awarded an exclusive worldwide license agreement from Cedars-Sinai Medical Center in...Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination With FluMist Influenza Vaccine July 12, 2018
Hemispherx Biopharma, Inc. recently announced the filing of a clinical study report on AMP-600, a Phase I/II trial of intranasal...EXECUTIVE INTERVIEW - MilliporeSigma: Accelerating the Development & Manufacture of Gene Therapies, Immunotherapies & Viral Vaccines April 2, 2018
Dave Backer, Head of Virus & Gene Therapy Strategic Initiatives at MilliporeSigma, talks about his company’s expanding GMP capacity to speed development and manufacture of gene therapies, immunotherapies, and viral vaccines.
GLOBAL REPORT - 2017 Global Drug Delivery & Formulation Report: Part 1, a Global Review March 15, 2018
In part 1 of this 4-part series, PharmaCircle in collaboration with Drug Development & Delivery, focuses on the macro aspects of the 2017 product approvals.
Vaccinex & Catalent Biologics to Collaborate on Antibody-Drug Conjugate Development November 30, 2017
Catalent Pharma Solutions and Vaccinex, Inc. recently announced an agreement to develop an antibody-drug conjugate (ADC) using Catalent’s proprietary SMARTag®...Immunovaccine & Leidos Expand Collaboration November 27, 2017
Immunovaccine Inc. recently announced it is expanding its collaboration with Leidos to develop preventative, peptide-based malaria vaccine candidates. The US...Immuno-Oncology Looks Set to Become Fifth Pillar of Cancer Treatment September 18, 2017
Immuno-Oncology (IO) looks set to become the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and other targeted treatments...EXECUTIVE INTERVIEW - Viral Gene: Protein-Targeting Cancer Vaccine Could Boost Survival Rates January 13, 2017
Harry A. Arena, MBA, President & CEO of TDT, Chris Kim, President & General Counsel, Viral Gene, Inc., and Dr. Scott Waldman, Professor & Chair of Sidney Kimmel Medical College’s Department of Pharmacology & Experimental Therapeutics at Thomas Jefferson University, discuss the unique characteristics of the vaccine, the patients who will benefit the most, and how a research team captured the attention of investors.
Cancer Vaccines Market Will Soar to $7.5 Billion by 2022 November 17, 2016
The cancer vaccines market is set to almost triple from $2.5 billion in 2015 to $7.5 billion by 2022, representing...BioSun & ARTES Announce Co-Development Agreement for HPV Vaccine November 8, 2016
BioSun Pharmed and ARTES Biotechnology recently announced they will join forces for the development and manufacturing of a HPV (human...HCV MARKET - Recent Success in HCV Treatment Brings Relief to Patients but Challenges to Companies November 7, 2016
INTRODUCTION Driven by several novel regimens recently receiving approval in the US and in Europe, high cure rates exceeding...PROTEIN THERAPEUTICS MARKET - Technology Advances Spur Market Growth of Protein Therapies November 7, 2016
Laurie L. Sullivan and Shalini S. Dewan, BCC Research Analysts, believe with the advent of genetic engineering and recombinant DNA technology, it is now possible to produce a wide variety of human proteins, and that these novel technologies have lifted the market for therapeutic proteins to new heights.
